1. Effects of Recombinant Human Growth Hormone Treatment, Depending on the Therapy Start in Different Nutritional Phases in Paediatric Patients with Prader–Willi Syndrome: A Polish Multicentre Study
- Author
-
Lecka-Ambroziak, Agnieszka, Wysocka-Mincewicz, Marta, Doleżal-Ołtarzewska, Katarzyna, Zygmunt-Górska, Agata, Wędrychowicz, Anna, Żak, Teresa, Noczyńska, Anna, Birkholz-Walerzak, Dorota, Stawerska, Renata, Hilczer, Maciej, Obara-Moszyńska, Monika, Rabska-Pietrzak, Barbara, Gołębiowska, Elżbieta, Dudek, Adam, Petriczko, Elżbieta, Szalecki, Mieczysław, and Treatment, on behalf of the Polish Coordination Group for rhGH more...
- Subjects
0301 basic medicine ,growth hormone deficiency ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,insulin-like growth factor 1 ,Prader–Willi syndrome ,media_common.quotation_subject ,030209 endocrinology & metabolism ,Carbohydrate metabolism ,Article ,Growth hormone deficiency ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Internal medicine ,Medicine ,Mass index ,recombinant human growth hormone ,media_common ,medicine.diagnostic_test ,business.industry ,nutritional and metabolic diseases ,Bone age ,Appetite ,General Medicine ,Anthropometry ,medicine.disease ,030104 developmental biology ,Endocrinology ,Recombinant DNA ,business ,Lipid profile - Abstract
Recombinant human growth hormone (rhGH) treatment is an established management in patients with Prader–Willi syndrome (PWS), with growth promotion and improvement in body composition and possibly the metabolic state. We compared anthropometric characteristics, insulin-like growth factor 1 (IGF1) levels, metabolic parameters and the bone age/chronological age index (BA/CA) in 147 children with PWS, divided according to age of rhGH start into four groups, corresponding to nutritional phases in PWS. We analysed four time points: baseline, rhGH1 (1.21 ± 0.81 years), rhGH2 (3.77 ± 2.17 years) and rhGH3 (6.50 ± 2.92 years). There were no major differences regarding height SDS between the groups, with a higher growth velocity (GV) (p = 0.00) and lower body mass index (BMI) SDS (p <, 0.05) between the first and older groups during almost the whole follow-up. IGF1 SDS values were lower in group 1 vs. other groups at rhGH1 and vs. groups 2 and 3 at rhGH2 (p <, 0.05). Glucose metabolism parameters were favourable in groups 1 and 2, and the lipid profile was comparable in all groups. BA/CA was similar between the older groups. rhGH therapy was most effective in the youngest patients, before the nutritional phase of increased appetite. We did not observe worsening of metabolic parameters or BA/CA advancement in older patients during a comparable time of rhGH therapy. more...
- Published
- 2021
- Full Text
- View/download PDF